Alternatives to BioNTech

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Advancing next-generation mRNA medicines.

AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.

Developing novel therapeutics for challenging diseases using advanced biological insights.

Developing novel RNA-targeting compounds for cancer and rare genetic diseases.

Tech.Bio company advancing mRNA discovery with AI and its mRNA Lightning platform.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Immunotherapy company targeting oncology and autoimmune diseases.

Clinical-stage immunotherapy company developing novel treatments for cancer.

South Korean biopharmaceutical company developing novel biologics for cancer and rare diseases.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.